premature stop codon

3

An MDA grant will help develop RTC13, a drug designed to cause dystrophin protein production in DMD-affected muscle fibers

posted on February 9, 2011 - 11:39am
A new MDA translational research grant for $476,465 over three years will allow Carmen Bertoni at the University of California, Los Angeles (UCLA) to develop RTC13, an experimental compound designed to treat Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) caused by a specific type of flaw in the gene for the muscle protein dystrophin.